The molecule we have designed binds only to the HER2 protein extracellular domain and inhibits PPI of EGFR:HER2 and HER2:HER3 heterodimers that have important implications in breast, lung, and ovarian cancers. The gene discussed is ERBB2; the disease is ovarian cancer.